Q3 2024 EPS Estimates for Krystal Biotech, Inc. Boosted by Analyst (NASDAQ:KRYS)

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Equities researchers at William Blair lifted their Q3 2024 earnings per share (EPS) estimates for shares of Krystal Biotech in a research report issued to clients and investors on Monday, May 6th. William Blair analyst T. Lugo now expects that the company will earn $0.63 per share for the quarter, up from their prior forecast of $0.41. William Blair has a "Outperform" rating on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $1.82 per share. William Blair also issued estimates for Krystal Biotech's Q4 2024 earnings at $0.75 EPS, FY2024 earnings at $1.91 EPS, Q1 2025 earnings at $1.41 EPS, Q2 2025 earnings at $1.27 EPS, Q3 2025 earnings at $1.61 EPS, Q4 2025 earnings at $1.28 EPS, FY2025 earnings at $5.58 EPS, FY2026 earnings at $5.26 EPS and FY2027 earnings at $9.70 EPS.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Monday, May 6th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.20 by ($0.17). The business had revenue of $45.25 million for the quarter, compared to analyst estimates of $47.37 million. During the same period in the previous year, the business earned ($1.76) EPS. The company's quarterly revenue was up 452400.0% on a year-over-year basis.

A number of other equities analysts have also recently issued reports on the stock. Stifel Nicolaus reiterated a "buy" rating and issued a $204.00 price target (up previously from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. HC Wainwright reaffirmed a "buy" rating and set a $200.00 price objective on shares of Krystal Biotech in a research report on Monday. Citigroup upped their target price on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a "buy" rating in a research report on Tuesday, February 27th. Finally, Guggenheim boosted their target price on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a "buy" rating in a report on Tuesday, February 27th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $171.00.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock traded up $1.06 during midday trading on Thursday, hitting $158.74. The company had a trading volume of 197,304 shares, compared to its average volume of 361,986. Krystal Biotech has a 52-week low of $86.03 and a 52-week high of $189.97. The stock has a market capitalization of $4.53 billion, a P/E ratio of 84.89 and a beta of 0.91. The company has a 50 day moving average of $168.75 and a 200 day moving average of $134.44.

Insider Activity

In related news, CAO Kathryn Romano sold 8,087 shares of the company's stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $136.91, for a total value of $1,107,191.17. Following the completion of the sale, the chief accounting officer now directly owns 12,556 shares of the company's stock, valued at $1,719,041.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Krystal Biotech news, CAO Kathryn Romano sold 8,087 shares of the company's stock in a transaction on Monday, February 26th. The stock was sold at an average price of $136.91, for a total transaction of $1,107,191.17. Following the completion of the sale, the chief accounting officer now owns 12,556 shares in the company, valued at $1,719,041.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the transaction, the insider now owns 1,550,882 shares in the company, valued at $265,138,786.72. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,087 shares of company stock worth $6,210,591. Company insiders own 14.10% of the company's stock.

Hedge Funds Weigh In On Krystal Biotech

A number of large investors have recently made changes to their positions in KRYS. Scout Investments Inc. purchased a new position in Krystal Biotech during the 1st quarter worth $8,976,000. State Board of Administration of Florida Retirement System raised its position in shares of Krystal Biotech by 18.5% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 7,307 shares of the company's stock valued at $1,300,000 after purchasing an additional 1,140 shares during the last quarter. ProShare Advisors LLC grew its position in Krystal Biotech by 9.0% during the 1st quarter. ProShare Advisors LLC now owns 5,865 shares of the company's stock worth $1,044,000 after purchasing an additional 486 shares during the last quarter. Headlands Technologies LLC acquired a new position in Krystal Biotech during the 1st quarter valued at approximately $291,000. Finally, Sei Investments Co. increased its stake in Krystal Biotech by 128.3% during the 1st quarter. Sei Investments Co. now owns 33,752 shares of the company's stock valued at $6,005,000 after purchasing an additional 18,968 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).